CorMedix Inc
NASDAQ:CRMD

Watchlist Manager
CorMedix Inc Logo
CorMedix Inc
NASDAQ:CRMD
Watchlist
Price: 11.08 USD 4.92% Market Closed
Market Cap: 873m USD

CorMedix Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CorMedix Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
CorMedix Inc
NASDAQ:CRMD
Net Income (Common)
$162.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Income (Common)
$25.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income (Common)
$6B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Net Income (Common)
$9.8B
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Net Income (Common)
$19B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Net Income (Common)
$18.4B
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
23%
No Stocks Found

CorMedix Inc
Glance View

CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

CRMD Intrinsic Value
HIDDEN
Show

See Also

What is CorMedix Inc's Net Income (Common)?
Net Income (Common)
162.5m USD

Based on the financial report for Sep 30, 2025, CorMedix Inc's Net Income (Common) amounts to 162.5m USD.

Back to Top